赛诺菲计划全球提交关键湿疹新药申请,尽管三期试验结果喜忧参半
Sanofi plans global filings for key eczema prospect despite mixed phase 3 readout
生物技术与制药领域的最新动态
Sanofi plans global filings for key eczema prospect despite mixed phase 3 readout
Omics Lab Services: Global Market Review 2021-2025 and Forecast 2026-2031 Featuring Profiles of Agilent Technologies, Q2 Solutions, Flomics Biotech, QIAGEN, Thermo Fisher Scientific and More - Yahoo Finance
Universal Beteiligungs und Servicegesellschaft mbH Purchases 40,166 Shares of Illumina, Inc. $ILMN - MarketBeat
Rakuten Investment Management Inc. Purchases New Shares in Agilent Technologies, Inc. $A - MarketBeat
$4.5 Billion Whole Genome Sequencing Market Outlook, 2031 Featuring Profiles of Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies and Other Leading Players - Yahoo Finance Singapore
Cantillon Capital Management LLC Lowers Stock Holdings in Thermo Fisher Scientific Inc. $TMO - MarketBeat
10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - Finviz
10x Genomics Expands Clinical Ambitions As Momentum Outruns Analyst Targets - simplywall.st
Robust assessment of asymmetric division in colon cancer cells
Computational modelling identifies key determinants of subregion-specific dopamine dynamics in the striatum
Lonza Group (OTCMKTS:LZAGY) Sees Large Volume Increase - Time to Buy? - MarketBeat
10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - Stock Titan
10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - Yahoo Finance
Industry Roundtable: Small-Molecule APIs: What’s in Store for 2026? - DCAT Value Chain Insights
Why Illumina (ILMN) Is Up 5.9% After CMS Backs TruSight Oncology Comprehensive Reimbursement - simplywall.st
NIH imposes full ban of aborted fetal tissue in research
High court picked Hikma’s ‘skinny label’ fight after letting the issue ‘percolate’
Investors load Corxel with $287M for a ‘differentiated’ obesity pill
Drugmakers spent less on Washington lobbying in 2025's final quarter
Janux’s tumor-activated platform draws BMS in potential $850M deal